Perspective Chapter: Ketamine, Depression, and Gender Bias
Tahani K. Alshammari, Sarah Alseraye, Nouf M. Alrasheed, Anfal F. Bin Dayel, Asma S. Alonazi, Jawza F. Al Sabhan, Musaad A. Alshammari
Ketamine Revisited - New Insights into NMDA Inhibitors September 14, 2022 Peer reviewed DOI: 10.5772/intechopen.103656
Summary
The chapter reviews the differences between sexes in the context of depression and highlights the importance of considering gender in preclinical studies. It focuses on ketamine, which has been identified as a rapid antidepressant, and discusses its effects in both pharmacological and genetic models of depression. The aim is to enhance understanding of treatment resistance mechanisms and promote awareness of gender-related factors in mood disorder research.
Study at a glance
| Key finding | The chapter emphasizes the need to consider gender as a vital factor in examining depression and its treatment with ketamine. |
|---|
Abstract
Our knowledge regarding pathological and treatment resistance mechanisms involved in depression is far from understood. Sexual dimorphism in this topic is well acknowledged. However, the need to highlight sex-based discrepancies is unmet. Ketamine, the dissociative anesthetic, has emerged as a rapid antidepressant. This chapter reviewed sexual dimorphism in pharmacological and genetic models of depression, emphasizing ketamine-related antidepressant effects. Aiming by this report, we would extend our knowledge, highlight gender as one of the vital factors in examining depression in preclinical studies, and elucidate complex antidepressant effects associated with ketamine administration. Our central goal is to encourage neuroscientists to consider gender in their studies of mood disorders.